

CLAIMS

1. Method for prevention of capsular opacification, comprising:
- 5 a) creating an opening in a lens capsule of an eye;
 b) removing the natural lens from the lens capsule;
 c) inserting a capsule filling implant into the lens capsule; and
 d) injecting a composition into the space between
10 the inserted implant and the lens capsule;
 in which method the composition injected in step d) comprises at least one agent capable of inhibiting at least one of the following:
- 15 - proliferation of lens epithelial cells;
 - migration of lens epithelial cells; and
 - production of extra-cellular matrix by lens epithelial cells.
2. Method according to claim 1, in which step d) is
20 performed in such a way that the composition injected is applied to the germinative zones of epithelial cells, and in such a way that the central parts of the anterior and posterior surfaces of the lens capsule are kept essentially free from the composition.
- 25 3. Method according to claim 1, in which step d) is performed in such a way that the composition injected is applied to the whole of the inside of the lens capsule.
- 30 4. Method according to any one of the preceding claims, in which the injection in step d) is performed using an instrument having a hydrophobic outer surface.
- 35 5. Method according to claim 4, in which said instrument is a steel cannula with a hydrophobic coating.

6. Method according to claim 4, in which said instrument is made from a hydrophobic material.

7. Method according to any one of the preceding
5 claims, in which the size of the opening created in step a) is below 3 mm.

8. Method according to claim 7, in which the size of
the opening created in step a) is from 0.8 to 1.5 mm.
10

9. Method according to any one of the preceding
claims, which further comprises sealing the opening in
the lens capsule.

10. Method according to claim 9, in which said seal-
ing is performed through insertion of a sealing device in
the opening before step d), which sealing device permits
entrance into, and withdrawal from, the lens capsule of
instruments for manipulation and/or injection.
15

11. Method according to any one of the preceding
claims, in which the capsule filling implant is an arti-
ficial lens.
20

12. Method according to claim 11, in which the arti-
ficial lens is a capsule filling lens, such as selected
from hydrogel lenses, preformed lenses that are rolled
into a shape like a cigar, and lenses that are made from
lens material injected into the lens capsule and then
cured by heat or light.
25
30

13. Method according to any one of the preceding
claims, in which the capsule filling implant comprises an
injectable material, which is capable of undergoing
cross-linking to form a lens implant following injection
thereof into the lens capsule.
35

14. Method according to any one of the preceding claims, in which the at least one agent is present in a physiologically acceptable solution.

5 15. Method according to any one of the preceding claims, in which the at least one agent is present in a physiologically isotonic solution.

10 16. Method according to any one of the preceding claims, in which the at least one agent is present in a hypotonic solution.

15 17. Method according to any one of the preceding claims, in which the at least one agent is present in a hypertonic solution.

20 18. Method according to any one of the preceding claims, in which the composition comprises a cytotoxic agent.

25 19. Method according to claim 18, in which the cytotoxic agent is chosen from the group consisting of saporin, ricin, methotrexate, 5-fluorouracil, daunomycin, doxorubicin, mitoxanthrone, vinca alkaloids, vinblastine, colchicine, cytochasins, monensin, mitomycin and ouabain.

30 20. Method according to any one of the preceding claims, in which the composition comprises a nucleic acid molecule comprising a gene encoding a protein capable of inducing the death of lens epithelial cells, the gene being subject to transcriptional control specific to said cells.

35 21. Method according to claim 20, in which the gene encoding a protein capable of inducing the death of lens epithelial cells is chosen from the group consisting of genes encoding a protein which induces cell death by ne-

crosis and genes encoding a protein which is toxic to lens epithelial cells.

22. Method according to claim 21, in which the gene
5 encoding a protein capable of inducing the death of lens epithelial cells is a gene encoding a protein which induces apoptosis, or a gene involved in the process of apoptosis.

10 23. Method according to anyone of claims 20-22, in which said gene encoding a protein capable of inducing the death of lens epithelial cells is chosen from the genes encoding p53, BAX, FLICE, TRAIL and TRAIL-R.

15 24. Method according to any one of claims 20-23, in which the gene encoding a protein capable of inducing the death of lens epithelial cells is provided within a vector.

20 25. Method according to claim 24, in which said vector is of the adenovirus type.

26. Method according to any one of the preceding claims, in which the composition comprises at least one
25 basement membrane binding agent, which is conjugated to at least one cytotoxic agent.

27. Method according to claim 26, in which the at least one cytotoxic agent is chosen from the group consisting of ribosomal inhibitory proteins, antimitotic
30 drugs and ionophores.

28. Method according to claim 27, in which the at least one cytotoxic agent is a ribosomal inhibitory protein.
35

29. Method according to any one of claims 26-28, in which the at least one basement membrane binding agent is chosen from the group consisting of poly-L-lysine, poly-D-lysine, fibronectin, laminin, type I, II, III and IV
5 collagen, thrombospondin, vitronectin, polyarginine and platelet factor IV.

30. Method according to claim 29, in which the at least one basement membrane binding agent is chosen from
10 poly-L-lysine and poly-D-lysine.

31. Method according to any one of the preceding claims, in which the composition comprises a surfactant.

15 32. Method according to any one of the preceding claims, in which the composition comprises a hypotonic solution.

33. Method according to any one of the preceding
20 claims, in which the composition comprises a hypertonic solution.

34. Method according to any one of the preceding claims, in which the composition comprises a divalent
25 cation chelator.

35. Method according to any one of the preceding claims, in which the composition comprises an arginine-glycine-asparagine (RGID) peptide analog.
30

36. Method according to any one of the preceding claims, in which the composition comprises an antibody directed against cell attachment receptors.